1. Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM. Trends in hospitalisations in neonatal jaundice and kernicterus in the United States, 1988-2005. Pediatrics 2009; 123:524-32
2. National Institute for Health and Clinical Excellence. Neonatal Jaundice. (Clinical Guideline 98); 2010. Available from http://www.nice.org.uk/CG98. Last accessed 8th August 2016
3. Alcock GS, Liley. Immunoglobulin infusion for isoimmunehaemolytic jaundice in neonates.Cochrane Database Syst Rev. 2002; 3: CD003313
4. BO Olusanya, FB Osibanjo, CA Mabogunje, TM Slusher, SA Olowe. The burden and management of neonatal jaundice in Nigeria: A scoping review of the literature. NJCP 2016;19:1-17.
5. Ibekwe RC, Ibekwe MU, Muoneke VU. Outcome of Exchange blood transfusions done for neonatal jaundice in Abakaliki, South Eastern Nigeria. Journal of Clinical Neonatology. 2012;1:34-37
6. Owa JA, Ogunlesi TA. Why are we still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. World J Pediatr. 2009; 5:51-5
7. Nigerian consensus statement on newborn jaundice. Management of jaundice and prevention of extreme hyperbilirubinemia in infants ≥ 35 weeks gestation. Nigerian Expert Committee for severe hyperbilirubinemia (For NISONM)
8. Urbaniak SJ. ADCC (K Cell) lysis of human erythrocytes sensitized with Rhesus alloantibodies.II. Investigation into mechanism of lysis. Br J Haematol. 1979;42:315-328
9. Senterre T, Minon JM, Rigo J. Neonatal ABO incompatibility underlies a potentially severe hemolytic disease of the newborn and requires adequate care. Arch Pediatr. 2011;18:279-82
10. Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488-94
11. Greco C, Arnolda G, Boo NY, Iskander IF, Okolo AA, Rohsiswatmo R, et al. Neonatal jaundice in low- and middle- income countries: lessons and future directions from the 2015 Don Ostrow Trieste Yellow Retreat. Neonatology 2016;110:172-180
12. Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis]. Arch Pediatr. 2014; 21:976- 83.
13. Miqdad AM, Abdelbasit, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med. 2004;16:163-6.
14. R Gottstein, RWI Cooke. Systematic review of intravenous immunoglobulin in hemolytic disease of the newborn. Arch Dis Chil Fetal Neonatal Ed 2003;88: F6-F10
15. Neonatal jaundice treatment and management. emedicine.medscape.com. accessed 8th August 2016.
16. BO Olusanya, Tinuade A Ogunlesi, Praveen Kumar, NemYun boo, Iman F Iskander, Maria Fernanda B de Almeida, et al. Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings. BMC Paediatrics 2015;15:39